IVB期未分化甲状腺癌多模式治疗后辅助帕博利珠单抗治疗
本研究纳入IVB期未分化甲状腺癌患者,比较多模式治疗后辅助帕博利珠单抗与单纯观察的疗效。辅助组中位无进展生存期未达到,对照组为5.4个月(HR 0.24);辅助组中位总生存期未达到,对照组为31个月(HR 0.11)。作者认为辅助帕博利珠单抗似乎安全有效,但需验证性研究。
要点
- 辅助帕博利珠单抗组中位无进展生存期未达到,对照组为5.4个月(HR 0.24)。
- 辅助帕博利珠单抗组中位总生存期未达到,对照组为31个月(HR 0.11)。
核心结论
- 作者认为,辅助帕博利珠单抗似乎是预防IVB期未分化甲状腺癌患者多模式治疗后复发并延长生存的安全有效策略。
- 作者指出需要验证性研究。
研究设计与样本
- 研究纳入接受多模式治疗后辅助帕博利珠单抗的IVB期未分化甲状腺癌患者,数据来自一项因入组不佳提前终止的前瞻性2期试验和一项符合试验入组标准的连续患者回顾性队列。
- 辅助帕博利珠单抗在放疗完成后6周内开始。
- 选择年龄和治疗匹配的接受多模式治疗但未接受辅助帕博利珠单抗的对照组进行比较。
- 每臂16例患者,两组中位年龄均为59岁。
- 辅助帕博利珠单抗组中位PDL1评分为50%(范围0-95%)。
主要发现
- 辅助帕博利珠单抗组中位随访时间为24.3个月,对照组为56.7个月。
- 辅助帕博利珠单抗组中位无进展生存期未达到,对照组为5.4个月(CI: 2.04-16.20)(p = 0.006;HR 0.24 [CI: 0.08, 0.73])。
- 辅助帕博利珠单抗组中位总生存期未达到,对照组为31个月(CI: 13.9, NA)(p = 0.009;HR 0.11 [CI: 0.01, 0.83])。
- 对照组12个月和24个月生存率分别为80% [CI: 0.51-0.93]和52% [CI: 0.25-0.74],而辅助帕博利珠单抗组所有患者在1年和2年时均存活。
局限性
- 前瞻性2期试验因入组不佳提前终止。
- 作者指出需要验证性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid cancer (ATC) has historically been almost uniformly fatal. In patients with the loco-regional disease (stage IVB), multimodal therapy (upfront surgery when feasible, radiation +/- concurrent chemotherapy) followed by observation is the current standard of care. Methods: Stage IVB ATC patients treated with multimodal therapy, followed by adjuvant pembrolizumab were studied. Data were combined from a prospective, phase 2 trial that closed early due to poor accrual, and a retrospective cohort of consecutive patients who received adjuvant pembrolizumab, mirroring the trial eligibility criteria. Patients received adjuvant pembrolizumab starting within 6 weeks after completion of radiation. An age and treatment-matched control arm treated with multimodal therapy without adjuvant pembrolizumab was selected for comparison. The primary objectives included median progression-free survival (PFS) and recurrence rate, and the secondary objective was median overall survival (OS). Results: Sixteen patients were included in each arm. The median age in both groups was 59 years. The median PDL1 score in the adjuvant pembrolizumab arm was 50% (range, 0-95%). The majority (88%) had upfront surgery in both groups. The median follow-up time was 24.3 months in the adjuvant arm and 56.7 months in the control arm. The median PFS in the adjuvant and control arm was not reached, and 5.4 months [CI: 2.04-16.20], respectively (p = 0.006; HR 0.24 [CI: 0.08, 0.73]). The median OS was not reached in the adjuvant pembrolizumab group. In the control group, the median OS was 31 months [CI: 13.9, NA] (p = 0.009; HR 0.11 [CI: 0.01, 0.83]). The 12-and 24-month survival rates were 80% [CI: 0.51-0.93] and 52% [CI: 0.25-0.74], respectively, in the control arm, whereas all patients in the adjuvant arm were still alive at 1- and 2-years. Conclusion: Adjuvant pembrolizumab appears to be a safe and effective strategy to prevent recurrences and prolong survival in stage IVB ATC patients following multimodal therapy. Confirmatory studies are needed.
引用
- Cabanillas ME, Busaidy NL, Gunn GB, et al. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid. 2025. PMID: 40609521. doi:10.1089/thy.2025.0194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。